Literature DB >> 8719764

Importance of treatment time and blood pressure control in achieving long-term survival on dialysis.

B Charra1, M Calemard, G Laurent.   

Abstract

A drastic reduction in hemodialysis (HD) time has been based on the dialysis dose measurement in terms of urea Kt/V exclusively and on the use of high efficiency dialysers. It was subtly coupled to a de-emphasis of the use of HD to normalize blood pressure. In Tassin we have maintained long slow HD with an overall excellent patient survival. We analyze the influence of the different factors of this survival: the place of dry weight and blood pressure control without use of antihypertensive medication is emphasized, and the role of dialysis dose and nutrition is discussed. Adequacy should be defined in terms of these additive conditions. Long slow HD allows one to fulfill these conditions easily. Shortening of dialysis time should not interfere with the control of blood pressure.

Entities:  

Mesh:

Year:  1996        PMID: 8719764     DOI: 10.1159/000168968

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  20 in total

Review 1.  Cardiovascular complications of renal disease.

Authors:  A G Jardine; K McLaughlin
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

Review 2.  Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients.

Authors:  Rajiv Agarwal; Matthew R Weir
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

3.  Renal impairment, hypertension and plasma urotensin II.

Authors:  Ari Mosenkis; Radhakrishna R Kallem; Theodore M Danoff; Nambi Aiyar; Jonathan Bazeley; Raymond R Townsend
Journal:  Nephrol Dial Transplant       Date:  2010-07-09       Impact factor: 5.992

Review 4.  The relationship of volume overload and its control to hypertension in hemodialysis patients.

Authors:  Jennifer E Flythe; Nisha Bansal
Journal:  Semin Dial       Date:  2019-09-29       Impact factor: 3.455

5.  Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Francesca Tentori; Jinyao Zhang; Yun Li; Angelo Karaboyas; Peter Kerr; Rajiv Saran; Juergen Bommer; Friedrich Port; Takashi Akiba; Ronald Pisoni; Bruce Robinson
Journal:  Nephrol Dial Transplant       Date:  2012-03-19       Impact factor: 5.992

6.  Renal Association Clinical Practice Guideline on Haemodialysis.

Authors:  Damien Ashby; Natalie Borman; James Burton; Richard Corbett; Andrew Davenport; Ken Farrington; Katey Flowers; James Fotheringham; R N Andrea Fox; Gail Franklin; Claire Gardiner; R N Martin Gerrish; Sharlene Greenwood; Daljit Hothi; Abdul Khares; Pelagia Koufaki; Jeremy Levy; Elizabeth Lindley; Jamie Macdonald; Bruno Mafrici; Andrew Mooney; James Tattersall; Kay Tyerman; Enric Villar; Martin Wilkie
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

Review 7.  The controversies of diagnosing and treating hypertension among hemodialysis patients.

Authors:  Rajiv Agarwal
Journal:  Semin Dial       Date:  2012-06-11       Impact factor: 3.455

8.  Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure.

Authors:  Teena Tandon; Arjun D Sinha; Rajiv Agarwal
Journal:  Nephrol Dial Transplant       Date:  2013-01-24       Impact factor: 5.992

9.  Shorter dialysis times are associated with higher mortality among incident hemodialysis patients.

Authors:  Steven M Brunelli; Glenn M Chertow; Elizabeth D Ankers; Edmund G Lowrie; Ravi Thadhani
Journal:  Kidney Int       Date:  2010-01-20       Impact factor: 10.612

10.  The mortality risk of overhydration in haemodialysis patients.

Authors:  Volker Wizemann; Peter Wabel; Paul Chamney; Wojciech Zaluska; Ulrich Moissl; Christiane Rode; Teresa Malecka-Masalska; Daniele Marcelli
Journal:  Nephrol Dial Transplant       Date:  2009-01-07       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.